Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we cut back on antidepressants without harm? new study aims to find out

NCT ID NCT06796946

Disease control Sponsor: University of Huelva Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a supervised, gradual reduction of antidepressants can safely lower unnecessary long-term use in adults with mild depression or anxiety. Researchers will enroll 325 people from a health center in Spain who have taken antidepressants in the past year. The goal is to see if deprescribing improves quality of life without causing a return of symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deprescription of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, escitalopram)
What this could lead to
If successful, this could show that many people can safely reduce or stop antidepressants without worsening anxiety or depression, leading to better quality of life and fewer side effects.
What could go wrong
This is an early-phase trial with only 325 participants, so results may not apply to everyone. Some people might experience withdrawal symptoms or a return of depression or anxiety during dose reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 325 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * be of legal age (≥18 years), * have received at least one antidepressant prescription in the year before the start of the study, * and have the physical capacity to go to the health center and the mental capacity to give informed consent Exclusion Criteria: * minors, * have changed health centers, * have physical or mental disabilities (including advanced dementia, severe cognitive deficit, advanced Alzheimer's disease, and disability \>70%), or, * are hospitalized at the time of selection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antidepressants are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antidepressants Deprescription

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Antonio José Madueño-Caro

    Cadiz, 11006, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.